©2022 Stanford Medicine
Autologous Muscle Derived Cells for Female Urinary Sphincter Repair
Trial ID: NCT01893138
This randomized, double-blind, placebo-controlled, multicenter, confirmatory study will evaluate the efficacy and safety of Cook MyoSite Incorporated Autologous Muscle-Derived Cells (generic name Iltamiocel) compared to a placebo (vehicle) control dose in the treatment of stress urinary incontinence (SUI) in adult female patients.
A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence
- Female patient has primary symptoms of SUI, as confirmed by patient medical history
and clinical symptoms, including a focused incontinence evaluation.
- Patient has symptoms of pure urge incontinence as confirmed by basic evaluation of
etiology from a patient medical history, including a focused incontinence history.
- Patient has symptoms of mixed urinary incontinence where urge incontinence is the
- Patient has had stress urinary incontinence symptoms less than 6 months prior to
signing the informed consent.
- Patient has not previously attempted conservative treatment prior to signing the
informed consent. (Examples of conservative treatment include behavior modifications,
bladder exercises, biofeedback, etc.)
- Patient has more than 2 episode of awakening to void during normal sleeping hours.
- Patient cannot be maintained on a stable dose and/or frequency of medication
(including diuretics) known to affect lower urinary tract function, including but not
limited to, anticholinergics, tricyclic antidepressants or alpha-adrenergic blockers,
for at least 2 weeks prior to screening or is likely to change during the course of
- Patient is pregnant, lactating, or plans to become pregnant during the course of the
- Patient refuses to provide written informed consent.
- Patient is not at least 18 years of age.
- Patient is not available for the follow-up evaluations as required by the protocol.